nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

Area of Science:

• Oncology
• Clinical Trials
• Pharmacology

Background:

• Advanced non-small cell lung cancer (NSCLC) treatment has improved, yet specific patient groups remain underrepresented in clinical trials.
• Patients with comorbidities, including the elderly, those with renal impairment, diabetes, or poor performance status (ECOG PS 2), require careful efficacy and safety balancing.
• Limited clinical trial data exists for these vulnerable NSCLC patient populations.

Purpose of the Study:

• To perform a pooled analysis of clinical trial data to understand treatment outcomes in underrepresented NSCLC patient populations.
• To evaluate the efficacy and safety of nab-paclitaxel-based regimens in elderly patients, and those with renal impairment, diabetes, or ECOG PS 2.
• To provide evidence supporting the use of nab-paclitaxel in vulnerable NSCLC patient groups.

Main Methods:

• Pooled analysis of data from the ABOUND clinical trial program (ABOUND.SQM, ABOUND.PS2, ABOUND.70+) and a key phase III trial.
• Inclusion of elderly patients (≥ 70 years), patients with renal impairment (eGFR < 60 ml/min/1.73 m2), diabetes, or ECOG PS 2.
• Assessment of progression-free survival (PFS), overall survival (OS), overall response rates (ORR), and treatment-related adverse events.

Main Results:

• Median PFS ranged from 4.1 months (ECOG PS 2) to 7.7 months (diabetes).
• Median OS was highest in patients with renal impairment (18.2 months) and lowest in ECOG PS 2 patients (5.6 months).
• Overall response rates varied, with diabetes patients showing 56.9% and ECOG PS 2 patients 29.4%. Most adverse events were hematologic, including neutropenia, anemia, and thrombocytopenia.

Conclusions:

• Nab-paclitaxel-based regimens demonstrate efficacy in historically understudied NSCLC populations.
• While survival data for ECOG PS 2 patients were notably inferior, the findings support the use of these regimens in vulnerable groups.
• The study's results align with previous population-specific findings, reinforcing the utility of nab-paclitaxel in diverse NSCLC patient cohorts.